Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts Pharmaceutical Investing
Kite's Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma Pharmaceutical Investing
Gilead Exercises Option to License Nurix's IRAK4 Targeted Protein Degrader Development Candidate, NX-0479 Pharmaceutical Investing
InspireMD Announces Promotion of Andrea Tommasoli to Chief Operating Officer Pharmaceutical Investing
AbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI® in Plaque Psoriasis Patients With a Prior Suboptimal Response to IL-17 Inhibitor Therapy Pharmaceutical Investing
Phase 3 Study Shows XTANDI® plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer Pharmaceutical Investing
Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coformulation of Vibostolimab and Pembrolizumab, in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer Pharmaceutical Investing
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer's PAXLOVID Pharmaceutical Investing
Notice of Knight Therapeutics' Fourth Quarter and Year End 2022 Results Conference Call Pharmaceutical Investing
Janssen Announces Novel Dengue Antiviral Demonstrates Efficacy in Pre-Clinical Data Published in Nature Pharmaceutical Investing
